Other languages Ensysce Biosciences, Inc.

Equities

ENSC

US2936024056

Real-time Estimate Cboe BZX Other stock markets 10:13:00 2024-05-13 EDT			5-day change	1st Jan Change
0.578 ^USD	+10.31%		+2.97%	-45.02%

03-21	Transcript : Ensysce Biosciences, Inc., Q4 2023 Earnings Call, Mar 21, 2024
03-15	Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-15
Ensysce Biosciences Announces Successful Meeting with Fda for Pf614-Mpar, A Next Generation Opioid with Overdose Protection	02-21
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript	02-15
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain	01-31
Wall Street Set to Open Flat as Investors Eye Key Manufacturing Index	01-23
Ensysce Biosciences, Inc. Announces Key Efficacy Data for Lead Analgesic	12-14
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-Development of BupiZenge in the United States	11-28
Ensysce Biosciences, Inc. Announces Enrollment Completion for PF614-201 Clinical Study	11-16
Ensysce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Top Premarket Gainers	23-10-09
Ensysce Biosciences, Inc. Announces Completion of Site Initiation Visit for PF614-201 Clinical Study	23-09-26
Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies	23-09-14
Ensysce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11
Ensysce Biosciences, Inc. Announces Investigational Review Board Approval of Key Study Protocol	23-08-08
Ensysce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Ensysce Biosciences Closes $7 Million Public Offering	23-05-15
Top Midday Gainers	23-05-09
Ensysce Biosciences Says Study of Oral Human Abuse Potential of Drug Candidate for Pain Meets All Key Endpoints	23-04-03
Surging Oil Prices Trigger Fresh Inflation Worries, Driving Mixed Premarket Trading for US Equity Futures	23-04-03
Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ensysce Biosciences, Inc.

Equities

ENSC

US2936024056

Other languages

Filters